GlassScriptPhysician profile
Kanthi Menon
NPI 1205805298
$1,511.33
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $236 · 2022: $135.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $405.87 | 2019-2022 | |
| Alkermes, INC. | $232.65 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $125.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $125.12 | 2019-2020 | |
| Lundbeck LLC | $118.95 | 2019-2020 | |
| Allergan, INC. | $113.75 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $90.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.63 | 2019 | |
| Vanda Pharmaceuticals INC. | $47.99 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 | |
| Vertical Pharmaceuticals, LLC | $30.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.62 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.71 | 2019 | |
| Neurocrine Biosciences, INC. | $15.83 | 2019 | |
| Indivior INC. | $13.71 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $10.70 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanthi Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.